Brett Thibodeaux
Senior Scientist II at Vaxxinity- Claim this Profile
Click to upgrade to our gold package
for the full feature experience.
Topline Score
Bio
Adrian Timmers
Brett is a dedicated and creative virologist. At Novartis, he established a complicated model for viral replication as a model for viral conjuctivitis. His dedication and resourcefulness resulted in a dependable, productive model
Dr. Christopher H. Logue
I worked with Brett between 2006 and 2009 on a range of Arbovirus projects while at the Division of Vector Borne Infectious Diseases, CDC, Fort Collins. His attention to detail to the task at hand and commitment to completing tasks within their time-frame was very impressive. Brett could work on several projects at once, while ensuring that the outcomes of each were of an excellent quality. Brett was also excellent at training others on the broad range of techniques and protocols he has developed over the years. I would highly recommend Brett to manage and run a research group in cutting edge molecular assay development and traditional virology techniques alike.
Adrian Timmers
Brett is a dedicated and creative virologist. At Novartis, he established a complicated model for viral replication as a model for viral conjuctivitis. His dedication and resourcefulness resulted in a dependable, productive model
Dr. Christopher H. Logue
I worked with Brett between 2006 and 2009 on a range of Arbovirus projects while at the Division of Vector Borne Infectious Diseases, CDC, Fort Collins. His attention to detail to the task at hand and commitment to completing tasks within their time-frame was very impressive. Brett could work on several projects at once, while ensuring that the outcomes of each were of an excellent quality. Brett was also excellent at training others on the broad range of techniques and protocols he has developed over the years. I would highly recommend Brett to manage and run a research group in cutting edge molecular assay development and traditional virology techniques alike.
Adrian Timmers
Brett is a dedicated and creative virologist. At Novartis, he established a complicated model for viral replication as a model for viral conjuctivitis. His dedication and resourcefulness resulted in a dependable, productive model
Dr. Christopher H. Logue
I worked with Brett between 2006 and 2009 on a range of Arbovirus projects while at the Division of Vector Borne Infectious Diseases, CDC, Fort Collins. His attention to detail to the task at hand and commitment to completing tasks within their time-frame was very impressive. Brett could work on several projects at once, while ensuring that the outcomes of each were of an excellent quality. Brett was also excellent at training others on the broad range of techniques and protocols he has developed over the years. I would highly recommend Brett to manage and run a research group in cutting edge molecular assay development and traditional virology techniques alike.
Adrian Timmers
Brett is a dedicated and creative virologist. At Novartis, he established a complicated model for viral replication as a model for viral conjuctivitis. His dedication and resourcefulness resulted in a dependable, productive model
Dr. Christopher H. Logue
I worked with Brett between 2006 and 2009 on a range of Arbovirus projects while at the Division of Vector Borne Infectious Diseases, CDC, Fort Collins. His attention to detail to the task at hand and commitment to completing tasks within their time-frame was very impressive. Brett could work on several projects at once, while ensuring that the outcomes of each were of an excellent quality. Brett was also excellent at training others on the broad range of techniques and protocols he has developed over the years. I would highly recommend Brett to manage and run a research group in cutting edge molecular assay development and traditional virology techniques alike.
Experience
-
Vaxxinity
-
United States
-
Biotechnology Research
-
1 - 100 Employee
-
Senior Scientist II
-
Mar 2022 - Present
-
-
-
Florida Health
-
United States
-
Government Administration
-
700 & Above Employee
-
Biological Scientist IV
-
Apr 2020 - Mar 2022
-
-
-
MRIGlobal
-
United States
-
Research Services
-
200 - 300 Employee
-
Principal Scientist
-
Aug 2018 - Sep 2019
-
-
-
Novartis Institutes for BioMedical Research (NIBR)
-
United States
-
Pharmaceutical Manufacturing
-
700 & Above Employee
-
Investigator III - Lab Head - Ophthalmology
-
Mar 2017 - Aug 2018
-
-
Investigator II - Lab Head - Ocular Infections
-
Sep 2013 - Mar 2017
-
-
-
Novartis Institutes for BioMedical Research (NIBR)
-
United States
-
Pharmaceutical Manufacturing
-
700 & Above Employee
-
Senior Scientist II - External Disease - Anti-Infectives
-
Nov 2011 - Jun 2013
Developed and characterized in vivo viral keratoconjunctivitis models that were used to evaluate novel antiviral therapeutics Designed plaque assay procedure for high throughput processing of viral samples Implemented protocols for quantification of viral DNA and mRNA from in vivo samples by quantitative PCR Managed and supported laboratory personnel performing in vivo testing and quantification Prepared and presented experimental compound evaluation reports based on in vivo data Show less
-
-
-
Colorado State University
-
United States
-
Higher Education
-
700 & Above Employee
-
Research Scientist I
-
Aug 2009 - Nov 2011
Principal Investigator on NIH/NIAID Regional Centers of Excellence Career Development grant designed to develop a viscerotropic, small animal, peripheral challenge model of yellow fever (YF) to evaluate combination of mAbs and novel antiviral/anti-inflammatory agents as possible therapeuticsSupervisor on separate NIH/NIAID Regional Centers of Excellence grant in charge of development of human-murine chimeric antibodies for therapy of YF, dengue, and Venezuelan equine encephalitisDeveloped a BSL-2 viscerotropic strain of YF through successive passage of YF 17D-204 vaccine strain in mouse livers and hepatic cell cultureSequenced viscerotropic passage strains of 17D-204 to monitor mutations in viral genome associated with enhanced liver growthGenerated inflammation profile of viscerotropic model by measuring inflammatory cytokine, chemokine and serum factor levels throughout infectionUsed viscerotropic model to evaluate the prophylactic and therapeutic protection provided by mAbs and antiviral/anti-inflammatory compounds Show less
-
-
Research Associate III
-
2007 - Aug 2009
Developed a small animal peripheral challenge model of yellow feverDeveloped human-murine chimeric IgG and IgM for prophylaxis and therapy of yellow feverDemonstrated protective and therapeutic benefit of human-murine chimeric IgG or IgM in yellow fever small animal peripheral challenge model
-
-
-
Centers for Disease Control and Prevention
-
United States
-
Government Administration
-
700 & Above Employee
-
Postdoctoral Fellow
-
Jul 2005 - Jun 2007
Developed human-murine chimeric antibodies (IgM and IgG) from flavivirus and alphavirus group-specific murine monoclonal antibodies Confirmed virus-specific activity of chimeric antibodies by screening against panels of viral antigens Incorporated 4 chimeric antibodies into standard CDC diagnostic assays for arboviral surveillance Developed human-murine chimeric antibodies (IgM and IgG) from flavivirus and alphavirus group-specific murine monoclonal antibodies Confirmed virus-specific activity of chimeric antibodies by screening against panels of viral antigens Incorporated 4 chimeric antibodies into standard CDC diagnostic assays for arboviral surveillance
-
-
Education
-
1998 - 2005
Louisiana State University School of Medicine in New Orleans
Doctor of Philosophy (Ph.D.), Microbiology, Immunology, and Parasitology -
1992 - 1996
University of Louisiana at Lafayette
Bachelor of Science (B.S.), Microbiology, General
Community
